Clinical Trial Update: Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating epacadostat with pembrolizumab in head and neck cancer that progressed after prior immunotherapy; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Epacadostat (epacadostat)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-01-27